Christian Schetter

Dr. Christian Schetter studied biology and earned his Ph.D. in molecular biology at the Institute of Genetics, University of Cologne, Germany. Prior to joining Rentschler Biopharma, Dr. Christian Schetter was Managing Director at Arix Bioscience plc, UK, responsible for investment decisions as well as scientific evaluations and served in support functions for portfolio companies. As CEO of Rigontec GmbH (now MSD / Merck & Co., USA), he was responsible for the successful acquisition by MSD and continued to serve as CEO of Rigontec GmbH, an MSD Company, after closing of the transaction. Previously, he was President & CEO for Fresenius Biotech GmbH (now Neovii Biotech) and Senior VP as well as Managing Director of Coley Pharmaceutical Group (now Pfizer).

Dr. Schetter is also Non-Executive Chairman of STipe Therapeutics, Chairman of the Supervisory Board of Eternygen GmbH and Independent Board Member of OMEICOS Therapeutics GmbH. Dr. Schetter has held several scientific positions, including at Scripps Research Institute, La Jolla, CA, USA, and as Senior Research Associate at the Max Planck Institute for Biochemistry, Martinsried, Germany. Dr. Christian Schetter has been Chief Scientific Officer of Rentschler Biopharma SE since September 15, 2021.